| Potent inhibitor of the main protease of SARS-CoV-2, co-packaged with a pharmacokinetic booster |
| Administered orally twice daily for 5 days |
| Reduces the risk of hospitalization or death in patients at high risk of progressing to severe COVID-19 |
| Generally well tolerated |
| May be associated with significant drug–drug interactions |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.